GlassScriptPhysician profile
Gregory Schleis
NPI 1154783207
$1,555.26
in general payments reported to CMS, 2019-2025
20 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $76.96 · 2022: $621 · 2023: $637 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $266.11 | 2021-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Lilly USA, LLC | $212.23 | 2022-2023 | Mounjaro, Jardiance, Baqsimi |
| Novo Nordisk INC | $171.14 | 2022-2023 | Wegovy |
| Abbott Laboratories | $148.64 | 2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $119.70 | 2021-2023 | Unithroid |
| Sanofi-Aventis U.S. LLC | $84.14 | 2022-2023 | |
| Insulet Corporation | $75.87 | 2023 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.05 | 2021-2023 | Jardiance, Synjardy, Tradjenta |
| Sequel Med Tech, LLC | $71.97 | 2025 | Twiist |
| Medtronic, INC. | $63.78 | 2022-2023 | Minimed 780g, Minimed 770g |
| Astrazeneca Pharmaceuticals LP | $46.17 | 2021-2022 | |
| Abbvie INC. | $29.34 | 2023 | Synthroid |
| Tandem Diabetes Care, INC. | $28.15 | 2022 | |
| Cequr Corporation | $27.93 | 2022-2023 | Cequr Simplicity |
| Ultragenyx Pharmaceutical INC. | $25.87 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $25.58 | 2023 | |
| Recordati_rare_diseases_inc. | $21.86 | 2022 | |
| Eusa Pharma (US) LLC | $21.86 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.74 | 2023 | Gvoke Hypopen |
| Amgen INC. | $19.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Schleis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.